TY - JOUR
T1 - PSA Velocity Is Associated With Gleason Score in Radical Prostatectomy Specimen
T2 - Marker for Prostate Cancer Aggressiveness
AU - Loeb, Stacy
AU - Sutherland, Douglas E.
AU - D'Amico, Anthony V.
AU - Roehl, Kimberly A.
AU - Catalona, William J.
N1 - Funding Information:
This study was supported in part by the Urological Research Foundation and Beckman Coulter, Inc., Fullerton, CA.
PY - 2008/11
Y1 - 2008/11
N2 - Objectives: Conflicting evidence has been reported on the association of prostate-specific antigen velocity (PSAV) with Gleason score in prostate needle biopsy specimens. The Gleason score is an important prognostic indicator for men with prostate cancer, and, in modern practice, it frequently affects treatment decisions. To our knowledge, the relationship between preoperative PSAV and Gleason score in the radical prostatectomy specimen has not been formally demonstrated. Methods: A total of 1049 men treated with radical prostatectomy had data on PSAV and Gleason score. Statistical analysis was performed to examine the relationship between the preoperative PSAV and the prostatectomy Gleason score and other adverse tumor features. Results: The median preoperative PSAV was 0.84, 0.97, and 1.39 ng/mL/y in men with a Gleason score of 6, 7, and 8-10, respectively (P = .05). A PSAV greater than 2 ng/mL/y was significantly associated with a prostatectomy Gleason score of 7 or greater on univariate and multivariate analysis. In addition, the preoperative PSAV was significantly lower in men with organ-confined disease (0.82 vs 1.17 ng/mL/y, respectively, P = .002). Conclusions: Our results have further validated PSAV as a marker for prostate cancer aggressiveness. The preoperative PSAV was a significant independent predictor of the Gleason score and non-organ-confined disease in the radical prostatectomy specimen. Thus, PSAV could be useful in treatment decision-making and in assessing the likelihood of long-term cancer control in men with prostate cancer.
AB - Objectives: Conflicting evidence has been reported on the association of prostate-specific antigen velocity (PSAV) with Gleason score in prostate needle biopsy specimens. The Gleason score is an important prognostic indicator for men with prostate cancer, and, in modern practice, it frequently affects treatment decisions. To our knowledge, the relationship between preoperative PSAV and Gleason score in the radical prostatectomy specimen has not been formally demonstrated. Methods: A total of 1049 men treated with radical prostatectomy had data on PSAV and Gleason score. Statistical analysis was performed to examine the relationship between the preoperative PSAV and the prostatectomy Gleason score and other adverse tumor features. Results: The median preoperative PSAV was 0.84, 0.97, and 1.39 ng/mL/y in men with a Gleason score of 6, 7, and 8-10, respectively (P = .05). A PSAV greater than 2 ng/mL/y was significantly associated with a prostatectomy Gleason score of 7 or greater on univariate and multivariate analysis. In addition, the preoperative PSAV was significantly lower in men with organ-confined disease (0.82 vs 1.17 ng/mL/y, respectively, P = .002). Conclusions: Our results have further validated PSAV as a marker for prostate cancer aggressiveness. The preoperative PSAV was a significant independent predictor of the Gleason score and non-organ-confined disease in the radical prostatectomy specimen. Thus, PSAV could be useful in treatment decision-making and in assessing the likelihood of long-term cancer control in men with prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=54449098163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=54449098163&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2008.01.082
DO - 10.1016/j.urology.2008.01.082
M3 - Article
C2 - 18571700
AN - SCOPUS:54449098163
SN - 0090-4295
VL - 72
SP - 1116
EP - 1120
JO - Urology
JF - Urology
IS - 5
ER -
